-
Milestone Pharmaceuticals Inc. (NASDAQ: MIST)
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to the development of new treatment approaches that provide patients with an active role in self-managing their care. Milestone’s lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat highly symptomatic episodic attacks associated with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR).
The company recently submitted a New Drug Application to the U.S. Food and Drug Administration for etripamil, which will be marketed under the conditionally approved brand name CARDAMYSTTM for PSVT, a debilitating heart condition where patients have unpredictable episodes of extremely rapid heart rate. If approved, it will be the first innovative treatment solution for PSVT in 30 years. Milestone is also studying etripamil in AFib-RVR, an irregular heart rhythm with an abnormally rapid heart rate. Results from the ReVeRA Phase 2 clinical trial were presented as a Featured Science Session at the American Heart Association Scientific Sessions 2023 and simultaneously published in Circulation: Arrhythmia and Electrophysiology. The data showed that delivery of etripamil nasal spray significantly and rapidly reduced ventricular rate in patients with AFib, along with symptoms of rapid rates, consistent with the drug’s pharmacologic profile. Find out more at www.milestonepharma.com.
Lorenz Muller
Chief Commercial Officer
Mr. Muller has served as Milestone’s Chief Commercial Officer since October 2017. Mr. Muller has almost 30 years of pharmaceutical industry experience where he served startup-to-large multinational companies. Prior to joining Milestone, he led the marketing team at Exact Sciences Corporation with accountability for developing and implementing all aspects of Exact Sciences’ marketing plans. Before that Mr. Muller led the thrombosis franchise at Daiichi Sankyo with US responsibility for the launch and Profit and Loss of cardiovascular blood-thinning drugs Effient® (prasugrel) and Savaysa® (edoxaban). Prior to Daiichi Sankyo, he was Vice President of Marketing and Healthcare Outcomes at CV Therapeutics, where he played a foundational role in the transition of the company from an R&D company to a commercial organization and oversaw the launch of Ranexa® (ranolazine), a first-in-class treatment for chronic angina.
Before joining CV Therapeutics, Mr. Muller held various positions in sales and marketing at Merck & Co., Inc., including product management as part of the hypertension and heart failure business group. He also served as a consultant for Arthur D. Little, Inc, for five years completing technology-based consulting assignments for a large number of biotechnology, pharmaceutical, and fine chemical clients.
Mr. Muller received a BS in both Chemical Engineering and Life Sciences and a MS in Chemical Engineering from the Massachusetts Institute of Technology. He earned his MBA from the Harvard Graduate School of Business Administration.